KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Gross Margin (2016 - 2025)

Jazz Pharmaceuticals has reported Gross Margin over the past 16 years, most recently at 87.18% for Q4 2025.

  • Quarterly results put Gross Margin at 87.18% for Q4 2025, down 99.0% from a year ago — trailing twelve months through Dec 2025 was 116.64% (up 2760.0% YoY), and the annual figure for FY2025 was 88.21%, down 84.0%.
  • Gross Margin for Q4 2025 was 87.18% at Jazz Pharmaceuticals, down from 88.56% in the prior quarter.
  • Over the last five years, Gross Margin for JAZZ hit a ceiling of 93.39% in Q1 2021 and a floor of 82.67% in Q3 2021.
  • Median Gross Margin over the past 5 years was 88.17% (2024), compared with a mean of 87.44%.
  • Biggest five-year swings in Gross Margin: plummeted -1012bps in 2021 and later skyrocketed 662bps in 2023.
  • Jazz Pharmaceuticals' Gross Margin stood at 84.82% in 2021, then fell by -2bps to 82.78% in 2022, then increased by 8bps to 89.4% in 2023, then dropped by -1bps to 88.17% in 2024, then decreased by -1bps to 87.18% in 2025.
  • The last three reported values for Gross Margin were 87.18% (Q4 2025), 88.56% (Q3 2025), and 88.88% (Q2 2025) per Business Quant data.